Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Sell
31
QGEN Quote, Financials, Valuation and Earnings
Last price:
$40.05
Seasonality move
:
2.99%
Day range:
$39.38 - $40.20
52-week range:
$37.63 - $49.30
Dividend yield:
0%
P/E ratio:
105.61x
P/S ratio:
4.38x
P/B ratio:
2.39x
Volume:
1.5M
Avg. volume:
1.1M
1-year change:
-9.62%
Market cap:
$8.5B
Revenue:
$2B
EPS (TTM):
$0.37
Analysts' Opinion
-
Consensus RatingQiagen NV has received a consensus rating of Hold. The company's average rating is a Hold based on 6 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $49.80, Qiagen NV has an estimated upside of 26.07% from its current price of $39.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $42.00 representing -6.33% downside risk from its current price of $39.50.
Fair Value
-
According to the consensus of 14 analysts, Qiagen NV has 26.07% upside to fair value with a price target of $49.80 per share.
QGEN vs. S&P 500
-
Over the past 5 trading days, Qiagen NV has overperformed the S&P 500 by 0.64% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Qiagen NV does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Qiagen NV has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Qiagen NV reported revenues of $521.2M.
Earnings Growth
-
Qiagen NV earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Qiagen NV reported earnings per share of $0.40.
Enterprise value:
8.8B
EV / Invested capital:
--
Price / LTM sales:
4.38x
EV / EBIT:
53.19x
EV / Revenue:
4.44x
PEG ratio (5yr expected):
--
EV / Free cash flow:
17.47x
Price / Operating cash flow:
17.27x
Enterprise value / EBITDA:
23.83x
Gross Profit (TTM):
$967.4M
Return On Assets:
1.42%
Net Income Margin (TTM):
4.23%
Return On Equity:
2.33%
Return On Invested Capital:
1.63%
Operating Margin:
27.08%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $2.1B | $2B | $2B | $509.2M | $521.2M | |
| Gross Profit | $1.4B | $1.2B | $967.4M | $316.1M | $333.3M | |
| Operating Income | $576.2M | $445.2M | $199.9M | $121.5M | $141.2M | |
| EBITDA | $779.4M | $688.6M | $368.3M | $182.9M | $182.5M | |
| Diluted EPS | $1.95 | $1.54 | $0.37 | $0.45 | $0.40 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.6B | $2.1B | $2.4B | $2.1B | $2B | |
| Total Assets | $5.9B | $6.1B | $6.3B | $6.1B | $5.7B | |
| Current Liabilities | $572.2M | $1.5B | $974.5M | $1.1B | $543.6M | |
| Total Liabilities | $3.1B | $3.1B | $2.8B | $2.3B | $2.1B | |
| Total Equity | $2.8B | $3.1B | $3.5B | $3.8B | $3.6B | |
| Total Debt | $1.9B | $1.9B | $1.9B | $1.5B | $1.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $715.3M | $459.5M | $673.6M | $151.4M | $191.5M | |
| Cash From Investing | -$726.8M | -$87.7M | -$249.2M | -$58.5M | -$6.8M | |
| Cash From Financing | -$125.8M | -$433.8M | -$422.9M | -$7.4M | -$489M | |
| Free Cash Flow | $565.9M | $296.7M | $502.3M | $99.1M | $141.9M | |
QGEN
Sector
Market Cap
$8.5B
$35.9M
Price % of 52-Week High
80.12%
42.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.03%
1-Year Price Total Return
-9.62%
-44.4%
Beta (5-Year)
0.624
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$39.73
200-day SMA
Sell
Level
$44.12
Bollinger Bands (100)
Sell
Level
40.08 - 46.36
Chaikin Money Flow
Buy
Level
203.7M
20-day SMA
Sell
Level
$39.53
Relative Strength Index (RSI14)
Sell
Level
45.71
ADX Line
Sell
Level
18.09
Williams %R
Neutral
Level
-50.6579
50-day SMA
Sell
Level
$41.03
MACD (12, 26)
Sell
Level
-0.21
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
101.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.1429)
Buy
CA Score
(Annual)
Level (0.3648)
Buy
Beneish M-Score
(Annual)
Level (-2.8925)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (0.1479)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Stock Forecast FAQ
In the current month, QGEN has received 6 Buy ratings 8 Hold ratings, and 0 Sell ratings. The QGEN average analyst price target in the past 3 months is $49.80.
-
Where Will Qiagen NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that Qiagen NV share price will rise to $49.80 per share over the next 12 months.
-
What Do Analysts Say About Qiagen NV?
Analysts are divided on their view about Qiagen NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Qiagen NV is a Sell and believe this share price will drop from its current level to $42.00.
-
What Is Qiagen NV's Price Target?
The price target for Qiagen NV over the next 1-year time period is forecast to be $49.80 according to 14 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is QGEN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Qiagen NV is a Hold. 8 of 14 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of QGEN?
You can purchase shares of Qiagen NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Qiagen NV shares.
-
What Is The Qiagen NV Share Price Today?
Qiagen NV was last trading at $40.05 per share. This represents the most recent stock quote for Qiagen NV. Yesterday, Qiagen NV closed at $39.50 per share.
-
How To Buy Qiagen NV Stock Online?
In order to purchase Qiagen NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is up 5.41% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 8.84% over the past day.
